Two top pharma companies have exited the UK's voluntary medicines pricing agreement in protest at what the industry has said is a "punitive" system of revenue clawbacks, casting doubt on th
A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening "footprint, R&D, and manufacturing investments" in the country.
In response to the recent Association of British Pharmaceutical Industry (ABPI) report, which showed a sharp decline (41%) in clinical trials initiated by the UK in the period 2017 to 2021,
